Why Moderna Stock Was Sick on Monday

181
18
Favorite

Why Moderna Stock Was Sick on Monday

Motley Fool2022-03-08

What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

181

Report

Comment（18）

Gladys8jk
·2022-03-09
Ok
Reply
1
Report
74rk
·2022-03-09
nice pun
Reply
2
Report
Cockatoo
·2022-03-08
👍
Reply
4
Report
来人
·2022-03-08
Wait....
Reply
3
Report
Dalex1212
·2022-03-08
Wat go up fast will come down faster
Reply
3
Report
Priya
·2022-03-08
Like
Reply
3
Report
CIG
·2022-03-08
同病相憐
Reply
3
Report
breAkdaWn
·2022-03-08
This is another drive down n down to buy. And then to sell high! Follow this trend.
Reply
Like
Report
DarkFate
·2022-03-08
Like
Reply
8
Report
xiaobaii
·2022-03-08
like & comment please
Reply
Like
Report
missychatty
·2022-03-08
Ok
Reply
9
Report
LISEE
·2022-03-08
Ok
Reply
9
Report
MdmPhua
·2022-03-08
Ok
Reply
7
Report
WinzWorld
·2022-03-08
Nice! 🤓
Reply
7
Report
KukuSaguru
·2022-03-08
Great
Reply
3
Report
chelseaeng
·2022-03-08
Like pls
Reply
7
Report
Ahdesfrmsg
·2022-03-08
Ok
Reply
5
Report
KW1
·2022-03-08
Ok
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1145029043?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-08 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145029043","market":"us","top_or_hot":-1,"title":"Why Moderna Stock Was Sick on Monday","media":"Motley Fool","content":"<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","article_id":"1145029043","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","pubTimestamp":1646706051,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"为什么莫德纳股票周一生病了","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9038185094,"gmtCreate":1646777500156,"gmtModify":1676534159845,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038185094","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038117959,"gmtCreate":1646775086027,"gmtModify":1676534159624,"author":{"id":"3584006131453100","authorId":"3584006131453100","name":"74rk","avatar":"https://static.tigerbbs.com/5d2cbf8ec63fa4fc1ffb7189ba15e1bc","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3584006131453100","authorIdStr":"3584006131453100"},"htmlText":"nice pun","listText":"nice pun","text":"nice pun","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038117959","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038363339,"gmtCreate":1646745296510,"gmtModify":1676534157232,"author":{"id":"4095668241594670","authorId":"4095668241594670","name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095668241594670","authorIdStr":"4095668241594670"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038363339","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038389053,"gmtCreate":1646742819977,"gmtModify":1676534156974,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"Wait....&nbsp;","listText":"Wait....&nbsp;","text":"Wait....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038389053","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038313598,"gmtCreate":1646739826030,"gmtModify":1676534156794,"author":{"id":"3585697030979497","authorId":"3585697030979497","name":"Dalex1212","avatar":"https://static.tigerbbs.com/bc5e5de5db287690289de51a25c7cfb0","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"3585697030979497","authorIdStr":"3585697030979497"},"htmlText":"Wat go up fast will come down faster","listText":"Wat go up fast will come down faster","text":"Wat go up fast will come down faster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038313598","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038337221,"gmtCreate":1646738657427,"gmtModify":1676534156722,"author":{"id":"3572737091790048","authorId":"3572737091790048","name":"Priya","avatar":"https://community-static.tradeup.com/news/985b5a05a7ab269956f359b5d70c86ba","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3572737091790048","authorIdStr":"3572737091790048"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038337221","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038932110,"gmtCreate":1646709181138,"gmtModify":1676534153780,"author":{"id":"3583974841960176","authorId":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"idStr":"3583974841960176","authorIdStr":"3583974841960176"},"htmlText":"同病相憐","listText":"同病相憐","text":"同病相憐","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038932110","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9038936612,"gmtCreate":1646709098297,"gmtModify":1676534153772,"author":{"id":"3569809505691000","authorId":"3569809505691000","name":"breAkdaWn","avatar":"https://community-static.tradeup.com/news/4c3676c14de9bfcd6f45bcf7ba4ddb6c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3569809505691000","authorIdStr":"3569809505691000"},"htmlText":"This is another drive down n down to buy. And then to sell high! Follow this trend.&nbsp;","listText":"This is another drive down n down to buy. And then to sell high! Follow this trend.&nbsp;","text":"This is another drive down n down to buy. And then to sell high! Follow this trend.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038936612","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038995271,"gmtCreate":1646707376739,"gmtModify":1676534153431,"author":{"id":"4097476142152970","authorId":"4097476142152970","name":"DarkFate","avatar":"https://static.tigerbbs.com/a22f6ff84fe185b6d3ad31b8673302d8","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"4097476142152970","authorIdStr":"4097476142152970"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038995271","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038998100,"gmtCreate":1646706862334,"gmtModify":1676534153350,"author":{"id":"3571345352614779","authorId":"3571345352614779","name":"xiaobaii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3571345352614779","authorIdStr":"3571345352614779"},"htmlText":"like &amp; comment please&nbsp;","listText":"like &amp; comment please&nbsp;","text":"like & comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038998100","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038993787,"gmtCreate":1646706737005,"gmtModify":1676534153322,"author":{"id":"3560333139103013","authorId":"3560333139103013","name":"missychatty","avatar":"https://static.tigerbbs.com/d75cdb42cbca99e3666b7b1796540245","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3560333139103013","authorIdStr":"3560333139103013"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038993787","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038993641,"gmtCreate":1646706667126,"gmtModify":1676534153314,"author":{"id":"3583882434595540","authorId":"3583882434595540","name":"LISEE","avatar":"https://static.itradeup.com/news/04e6b0d792206cfd74830f2552f37288","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583882434595540","authorIdStr":"3583882434595540"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038993641","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038993800,"gmtCreate":1646706650204,"gmtModify":1676534153314,"author":{"id":"3583814135262824","authorId":"3583814135262824","name":"MdmPhua","avatar":"https://static.itradeup.com/news/67971848be29673bfd9e494fe2e662e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583814135262824","authorIdStr":"3583814135262824"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038993800","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038993122,"gmtCreate":1646706643970,"gmtModify":1676534153308,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"htmlText":"Nice! 🤓","listText":"Nice! 🤓","text":"Nice! 🤓","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038993122","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038993906,"gmtCreate":1646706583129,"gmtModify":1676534153306,"author":{"id":"4101342491315650","authorId":"4101342491315650","name":"KukuSaguru","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4101342491315650","authorIdStr":"4101342491315650"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038993906","repostId":1145029043,"repostType":2,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038999315,"gmtCreate":1646706415941,"gmtModify":1676534153281,"author":{"id":"3581554242619885","authorId":"3581554242619885","name":"chelseaeng","avatar":"https://static.tigerbbs.com/9a09e299971ec473cf208e4d640b7c0f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581554242619885","authorIdStr":"3581554242619885"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038999315","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038990595,"gmtCreate":1646706378562,"gmtModify":1676534153273,"author":{"id":"4091358583248150","authorId":"4091358583248150","name":"Ahdesfrmsg","avatar":"https://static.tigerbbs.com/1c7beb9d76c8c0b998733ae7bb8974d8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4091358583248150","authorIdStr":"4091358583248150"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038990595","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9038907661,"gmtCreate":1646706114738,"gmtModify":1676534153234,"author":{"id":"3563714281601583","authorId":"3563714281601583","name":"KW1","avatar":"https://static.tigerbbs.com/094e3f8fd8b3de3da976515926ed1403","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":7,"crmLevelSwitch":1,"idStr":"3563714281601583","authorIdStr":"3563714281601583"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038907661","repostId":1145029043,"repostType":4,"repost":{"id":"1145029043","kind":"news","pubTimestamp":1646706051,"share":"https://ttm.financial/m/news/1145029043?lang=&edition=fundamental","pubTime":"2022-03-08 10:20","market":"us","language":"en","title":"Why Moderna Stock Was Sick on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1145029043","media":"Motley Fool","summary":"An analyst from a prominent investment bank shaves $20 off his price target on the shares.","content":"<html><head></head><body><p><b>What happened</b></p><p>Already contending with notable drops in COVID cases and fatalities, <b>Moderna</b> -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst&#39;s price-target cut that morning, and the shares fell by more than 7% on the day.</p><p><b>So what</b></p><p>The analyst in question was <b>Deutsche Bank</b>&#39;s Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8084a480fd34c819a3c33cf5ebcc6050\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>Referring to the company&#39;s fourth-quarter results, published in late February, Papadakis described Moderna&#39;s performance as &#34;relatively solid.&#34; He also views the stock as having &#34;good fundamental valuation support&#34; at the current price.</p><p><b>Now what</b></p><p>While Papadakis didn&#39;t seem overly impressed by Moderna&#39;s quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.</p><p>Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company&#39;s previous initiative, which had been fully utilized by the end of January.</p><p>The company&#39;s most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it&#39;s a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.</p><p></p><p></p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Sick on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Sick on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-08 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/03/07/why-moderna-stock-was-sick-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145029043","content_text":"What happenedAlready contending with notable drops in COVID cases and fatalities, Moderna -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.So whatThe analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.Image source: Getty Images.Referring to the company's fourth-quarter results, published in late February, Papadakis described Moderna's performance as \"relatively solid.\" He also views the stock as having \"good fundamental valuation support\" at the current price.Now whatWhile Papadakis didn't seem overly impressed by Moderna's quarter, the company did post a pair of convincing beats. Its per-share net profit was $11.29, which was significantly better than the average analyst estimate of $9.90. Revenue of $7.2 billion also topped expectations. Collectively, those prognosticators were modeling a top-line tally of just under $6.8 billion.Moderna also announced a major shareholder-pleasing move by unveiling a new share-repurchase program. This initiative will see the biotech buy back up to $3 billion worth of its stock, three times the amount of the company's previous initiative, which had been fully utilized by the end of January.The company's most recent news has generally been positive, and its coronavirus vaccine remains a go-to jab in many jurisdictions (including the U.S.). All in all, the stock has generally been on a tear through the pandemic. But now that COVID is (hopefully) fading somewhat, investors might be concerned that it's a bit of a one-trick pony, although it does have numerous, promising pipeline treatments in development.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":181,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}